Back to Search Start Over

Oncostatin M reduces atherosclerosis development in APOE*3Leiden.CETP mice and is associated with increased survival probability in humans.

Authors :
Keulen DV
Pouwer MG
Emilsson V
Matic LP
Pieterman EJ
Hedin U
Gudnason V
Jennings LL
Holmstrøm K
Nielsen BS
Pasterkamp G
Lindeman JHN
van Gool AJ
Sollewijn Gelpke MD
Princen HMG
Tempel D
Source :
PloS one [PLoS One] 2019 Aug 28; Vol. 14 (8), pp. e0221477. Date of Electronic Publication: 2019 Aug 28 (Print Publication: 2019).
Publication Year :
2019

Abstract

Objective: Previous studies indicate a role for Oncostatin M (OSM) in atherosclerosis and other chronic inflammatory diseases for which inhibitory antibodies are in development. However, to date no intervention studies with OSM have been performed, and its relation to coronary heart disease (CHD) has not been studied.<br />Approach and Results: Gene expression analysis on human normal arteries (n = 10) and late stage/advanced carotid atherosclerotic arteries (n = 127) and in situ hybridization on early human plaques (n = 9) showed that OSM, and its receptors, OSM receptor (OSMR) and Leukemia Inhibitory Factor Receptor (LIFR) are expressed in normal arteries and atherosclerotic plaques. Chronic OSM administration in APOE*3Leiden.CETP mice (n = 15/group) increased plasma E-selectin levels and monocyte adhesion to the activated endothelium independently of cholesterol but reduced the amount of inflammatory Ly-6CHigh monocytes and atherosclerotic lesion size and severity. Using aptamer-based proteomics profiling assays high circulating OSM levels were shown to correlate with post incident CHD survival probability in the AGES-Reykjavik study (n = 5457).<br />Conclusions: Chronic OSM administration in APOE*3Leiden.CETP mice reduced atherosclerosis development. In line, higher serum OSM levels were correlated with improved post incident CHD survival probability in patients, suggesting a protective cardiovascular effect.<br />Competing Interests: I have read the journal's policy and the authors of this manuscript have the following competing interests: Danielle van Keulen and Dennie Tempel are employed by Quorics B.V., Maarten D Sollewijn Gelpke by Molecular Profiling Consulting, Lori L Jennings by Novartis and Kim Holmstrøm and Boye Schnack Nielsen PhD by Bioneer A/S. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials,as detailed online in the guide for authors.

Details

Language :
English
ISSN :
1932-6203
Volume :
14
Issue :
8
Database :
MEDLINE
Journal :
PloS one
Publication Type :
Academic Journal
Accession number :
31461490
Full Text :
https://doi.org/10.1371/journal.pone.0221477